Quantifying the Influence of Gleason 6 Disease Labeling... - Dr. Alejandro Berlin

This video is a recording of Prostate Cancer Foundation Canada's 2024 Prostate Cancer Awareness Month Active Surveillance Support Group meeting held over Zoom. Dr. Ale Berlin is a staff clinician-scientist radiation oncologist at the Princess Margaret (PM) Cancer Center. He completed his training in Chile, Israel, and Canada. His clinical practice focuses on the discovery and clinical evaluation of novel therapeutics capitalizing on genomic characterization genitourinary malignancies, and advanced molecular and MR imaging. Dr. Berlin is a PI of the NRG GU010 study investigating the use of clinicogenomic risk stratification for treatment individualization in men with localized prostate cancer. Dr. Berlin also leads a clinical initiative quantifying the human and machine performance during the clinical deployment of an in-house developed AI radiotherapy planning method for prostate cancer. Dr. Alejandro Berlin speaks here on the impact of Gleason 6 being labelled as 'cancer' on treatment decision-making. For more information on Prostate Cancer Foundation Canada (formerly Prostate Cancer Foundation BC), a nonprofit proudly providing leadership and resources in prostate cancer support, awareness, and research since 1997, please visit: prostatecanada.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.